Regulatory Approvals

FDA Approves Zilurgisertib, an Oral ALK2 Inhibitor, for FOP

By

Regulatory Approvals — FDA Approves Zilurgisertib, an Oral ALK2 Inhibitor, for FOP  Pharmacy Times

Read the original at Regulatory Approvals ↗

Auto-published by the finit.news Events monitor from Regulatory Approvals; summarized by AI and may contain errors — verify against the primary source. September 28, 2026.

By

Related Post

Regulatory Approvals

Q&A: Cutlip on the SELUTION SLR DEB’s FDA Approval for Coronary In-Stent Restenosis

Regulatory Approvals

FDA Approves Tavapadon for the Treatment of Parkinson Disease

Regulatory Approvals

FDA Approves AbbVie’s Juvmo for Parkinson Disease

Financial News For All

Labor

Oregon’s public universities, classified workers narrowly avoid strike – Oregon Public Broadcasting

Regulatory Approvals

FDA Approves Zilurgisertib, an Oral ALK2 Inhibitor, for FOP

Regulatory Approvals

Roundup: FDA Approves Lilly’s Olumiant, AbbVie’s Juvmo, Mirum & Incyte’s Atebrioz

Regulatory Approvals

FDA Approves AbbVie’s Juvmo for Parkinson Disease